Home LiteratureArticle Details
PMID: 31747121 Published · ppublish English Journal Article Review

Metabolomics of lung cancer: Analytical platforms and their applications.

Journal of separation science ·Vol. 43 ·No. 1 ·2020-01-00 ·Pages 120-133

Noreldeen HAA, Liu X, Xu G

Abstract

Lung cancer is the leading type of cancer worldwide in terms of the number of new cases and is responsible for the largest number of deaths due to poor prognosis and difficult early detection. Due to its ability to detect numerous small molecular metabolites simultaneously, metabolomics has been widely used for the assessment of global metabolic changes in a living organism to discover candidate biomarkers for cancer diagnosis, investigate the development of cancer, and provide insights into the underlying pathophysiology. This review will mainly describe recent developments in lung cancer metabolomics in terms of early-stage detection, biomarker discovery and mechanism exploration by using nuclear magnetic resonance, liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, and capillary electrophoresis-mass spectrometry in the last 10 years. The sample collection and metabolite extraction methods are also summarized.

Keywords
capillary electrophoresis-mass spectrometry gas chromatography-mass spectrometry liquid chromatography-mass spectrometry lung cancer metabolomics
MeSH Terms
Electrophoresis, Capillary Gas Chromatography-Mass Spectrometry Humans Lung Neoplasms/diagnosis,drug therapy,metabolism Magnetic Resonance Spectroscopy Metabolomics
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Noreldeen Hamada A A
CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, P. R. China. | University of Chinese Academy of Sciences, Beijing, P. R. China. | Marine Chemistry Lab, Marine Environment Division, National Institute of Oceanography and Fisheries, Hurghada, Egypt.
Liu Xinyu ORCID
CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, P. R. China.
Xu Guowang
CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, P. R. China.
References (121)
121 references, click to expand
  1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394-424.
  2. Jackman, D. M., Johnson, B. E., Small-cell lung cancer. Lancet 2005, 366, 1385-1396.
  3. Bryant, A., Cerfolio, R. J., Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007, 132, 185-192.
  4. Bamji-Stocke, S., van Berkel, V., Miller, D. M., Frieboes, H. B., A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment. Metabolomics 2018, 14
  5. Pirozynski, M., 100 years of lung cancer. Respir. Med. 2006, 100, 2073-2084.
  6. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
  7. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., Adjei, A. A., Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584-594.
  8. Yu, L., Li, K., Zhang, X., Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review. Oncotarget 2017, 8, 115774-115786.
  9. Bjerrum, J. T., Metabonomics-Methods-and-Protocols. Springer 2015, 263.
  10. Wishart, D. S., Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug. Discov. 2016, 15, 473-484.
  11. Hori, S., Nishiumi, S., Kobayashi, K., Shinohara, M., Hatakeyama, Y., Kotani, Y., Hatano, N., Maniwa, Y., Nishio, W., Bamba, T., Fukusaki, E., Azuma, T., Takenawa, T., Nishimura, Y., Yoshida, M., A metabolomic approach to lung cancer. Lung Cancer 2011, 74, 284-292.
  12. Liu, X., Hoene, M., Yin, P., Fritsche, L., Plomgaard, P., Hansen, J. S., Nakas, C. T., Niess, A. M., Hudemann, J., Haap, M., Mendy, M., Weigert, C., Wang, X., Fritsche, A., Peter, A., Haring, H. U., Xu, G., Lehmann, R., Quality control of serum and plasma by quantification of (4E,14Z)-sphingadienine-C18-1-phosphate uncovers common preanalytical errors during handling of whole blood. Clin. Chem. 2018, 64, 810-819.
  13. Yin, P., Peter, A., Franken, H., Zhao, X., Neukamm, S. S., Rosenbaum, L., Lucio, M., Zell, A., Häring, H.-U., Xu, G., Lehmann, R., Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin. Chem. 2013, 59, 833.
  14. Yin, P., Lehmann, R., Xu, G., Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal. Bioanal. Chem. 2015, 407, 4879-4892.
  15. Bernini, P., Bertini, I., Luchinat, C., Nincheri, P., Staderini, S., Turano, P., Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J. Biomol. NMR 2011, 49, 231-243.
  16. Jopling, J., Henry, E., Wiedmeier, S. E., Christensen, R. D., Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics 2009, 123, e333-337.
  17. Lippi, G., Blanckaert, N., Bonini, P., Green, S., Kitchen, S., Palicka, V., Vassault, A. J., Plebani, M., Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin. Chem. Lab. Med. 2008, 46, 764-772.
  18. Hernandes, V. V., Barbas, C., Dudzik, D., A review of blood sample handling and pre-processing for metabolomics studies. Electrophoresis 2017, 38, 2232-2241.
  19. Kamlage, B., Maldonado, S. G., Bethan, B., Peter, E., Schmitz, O., Liebenberg, V., Schatz, P., Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin. Chem. 2014, 60, 399-412.
  20. Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J. D., Halsall, A., Haselden, J. N., Nicholls, A. W., Wilson, I. D., Kell, D. B., Goodacre, R., The Human Serum Metabolome Consortium, Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 2011, 6, 1060.
  21. Haukaas, T. H., Moestue, S. A., Vettukattil, R., Sitter, B., Lamichhane, S., Segura, R., Giskeødegård, G. F., Bathen, T. F., Impact of freezing delay time on tissue samples for metabolomic studies. Front. Oncol. 2016, 6
  22. Wedge, D. C., Allwood, J. W., Dunn, W., Vaughan, A. A., Simpson, K., Brown, M., Priest, L., Blackhall, F. H., Whetton, A. D., Dive, C., Goodacre, R., Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal. Chem. 2011, 83, 6689-6697.
  23. Vuckovic, D., Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2012, 403, 1523-1548.
  24. Barri, T., Dragsted, L. O., UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant. Anal. Chim. Acta 2013, 768, 118-128.
  25. Gonzalez-Covarrubias, V., Dane, A., Hankemeier, T., Vreeken, R. J., The influence of citrate, EDTA, and heparin anticoagulants to human plasma LC-MS lipidomic profiling. Metabolomics 2013, 9, 337-348.
  26. Denery, J. R., Nunes, A. A., Dickerson, T. J., Characterization of differences between blood sample matrices in untargeted metabolomics. Anal. Chem. 2011, 83, 1040-1047.
  27. Townsend, M. K., Clish, C. B., Kraft, P., Wu, C., Souza, A. L., Deik, A. A., Tworoger, S. S., Wolpin, B. M., Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. Clin. Chem. 2013, 59, 1657-1667.
  28. Yin, P., Zhou, L., Zhao, X., Xu, G., Sample collection and preparation of biofluids and extracts for liquid chromatography-mass spectrometry. Methods Mol. Biol. 2015, 1277, 51-59.
  29. Yuan, M., Breitkopf, S. B., Yang, X., Asara, J. M., A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 2012, 7, 872-881.
  30. Bi, H., Krausz, K. W., Manna, S. K., Li, F., Johnson, C. H., Gonzalez, F. J., Optimization of harvesting, extraction, and analytical protocols for UPLC-ESI-MS-based metabolomic analysis of adherent mammalian cancer cells. Anal. Bioanal. Chem. 2013, 405, 5279-5289.
  31. Dietmair, S., Timmins, N. E., Gray, P. P., Nielsen, L. K., Kromer, J. O., Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal. Biochem. 2010, 404, 155-164.
  32. Bennett, B. D., Yuan, J., Kimball, E. H., Rabinowitz, J. D., Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. Nat. Protoc. 2008, 3, 1299-1311.
  33. Chen, Y., Ma, Z., Li, A., Li, H., Wang, B., Zhong, J., Min, L., Dai, L., Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/mass spectrometry. J. Cancer Res. Clin. Oncol. 2015, 141, 705-718.
  34. Chen, Y., Ma, Z., Min, L., Li, H., Wang, B., Zhong, J., Dai, L., Biomarker identification and pathway analysis by serum metabolomics of lung cancer. BioMed Res. Int. 2015, 2015, 9.
  35. Deja, S., Porebska, I., Kowal, A., Zabek, A., Barg, W., Pawelczyk, K., Stanimirova, I., Daszykowski, M., Korzeniewska, A., Jankowska, R., Mlynarz, P., Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J. Pharm. Biomed. Anal. 2014, 100, 369-380.
  36. Mu, Y., Zhou, Y., Wang, Y., Li, W., Zhou, L., Lu, X., Gao, P., Gao, M., Zhao, Y., Wang, Q., Wang, Y., Xu, G., Serum metabolomics study of nonsmoking female patients with non-small cell lung cancer using gas chromatography-mass spectrometry. J. Proteome Res. 2019
  37. Liu, X., Li, J., Zheng, P., Zhao, X., Zhou, C., Hu, C., Hou, X., Wang, H., Xie, P., Xu, G., Plasma lipidomics reveals potential lipid markers of major depressive disorder. Anal. Bioanal. Chem. 2016, 408, 6497-6507.
  38. Li, J., Ren, S., Piao, H. L., Wang, F., Yin, P., Xu, C., Lu, X., Ye, G., Shao, Y., Yan, M., Zhao, X., Sun, Y., Xu, G., Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Sci. Rep. 2016, 6, 20984.
  39. Ros-Mazurczyk, M., Jelonek, K., Marczyk, M., Binczyk, F., Pietrowska, M., Polanska, J., Dziadziuszko, R., Jassem, J., Rzyman, W., Widlak, P., Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer 2017, 112, 69-74.
  40. Kami, K., Fujimori, T., Sato, H., Sato, M., Yamamoto, H., Ohashi, Y., Sugiyama, N., Ishihama, Y., Onozuka, H., Ochiai, A., Esumi, H., Soga, T., Tomita, M., Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 2013, 9, 444-453.
  41. Lorenz, M. A., Burant, C. F., Kennedy, R. T., Reducing time and increasing sensitivity in sample preparation for adherent mammalian cell metabolomics. Anal. Chem. 2011, 83, 3406-3414.
  42. Armitage, E. G., Barbas, C., Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 2014, 87, 1-11.
  43. Dumas, M. E., Maibaum, E. C., Teague, C., Ueshima, H., Zhou, B., Lindon, J. C., Nicholson, J. K., Stamler, J., Elliott, P., Chan, Q., Holmes, E., Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal. Chem. 2006, 78, 2199-2208.
  44. Keun, H. C., Ebbels, T. M., Antti, H., Bollard, M. E., Beckonert, O., Schlotterbeck, G., Senn, H., Niederhauser, U., Holmes, E., Lindon, J. C., Nicholson, J. K., Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. Chem. Res. Toxicol. 2002, 15, 1380-1386.
  45. Borgan, E., Sitter, B., Lingjaerde, OC., Johnsen, H., Lundgren, S., Bathen, T. F., Sørlie, T., Børresen-Dale, A. L., Gribbestad, I. S., Merging transcriptomics and metabolomics-advances in breast cancer profiling. BMC Cancer 2010, 10, 628.
  46. Zhang, X., Zhu, X., Wang, C., Zhang, H., Cai, Z., Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis. Oncotarget 2016, 7, 63437-63448.
  47. Van, Q. N., Veenstra, T. D., How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Med. 2009, 1, 5-5.
  48. Jeannerat D, F. J., NMR experiments for the analysis of mixtures: beyond 1D 1H spectra. Comb. Chem. High Throughput Screen 2012, 15, 15-35.
  49. Gruetter, R., Weisdorf, S. A., Rajanayagan, V., Terpstra, M., Merkle, H., Truwit, C., Garwood, M., Nyberg, S. L., Kamil, U., Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J. Magn. Reson. 1998, 135, 260-264.
  50. Grimes JH, O. C. T., The application of micro-coil NMR probe technology to metabolomics of urine and serum. J. Biomol. NMR 2011, 49, 297-305.
  51. Carrola, J., Rocha, C. M., Barros, A. S., Gil, A. M., Goodfellow, B. J., Carreira, I. M., Bernardo, J., Gomes, A., Sousa, V., Carvalho, L., Duarte, I. F., Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 2011, 10, 221-230.
  52. Rocha, C. M., Carrola, J., Barros, A. S., Gil, A. M., Goodfellow, B. J., Carreira, I. M., Bernardo, J., Gomes, A., Sousa, V., Carvalho, L., Duarte, I. F., Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 2011, 10, 4314-4324.
  53. Rocha, C. M., Barros, A. S., Goodfellow, B. J., Carreira, I. M., Gomes, A., Sousa, V., Bernardo, J., Carvalho, L., Gil, A. M., Duarte, I. F., NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 2015, 36, 68-75.
  54. Fan, T. W., Lane, A. N., Higashi, R. M., Farag, M. A., Gao, H., Bousamra, M., Miller, D. M., Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 2009, 8, 41.
  55. Emwas, A.-H. M., Salek, R. M., Griffin, J. L., Merzaban, J., NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics 2013, 9, 1048-1072.
  56. Lu, W., Su, X., Klein, M. S., Lewis, I. A., Fiehn, O., Rabinowitz, J. D., Metabolite measurement: pitfalls to avoid and practices to follow. Annu. Rev. Biochem. 2017, 86, 277-304.
  57. Bjerrum, J. T., Metabonomics: analytical techniques and associated chemometrics at a glance. Methods Mol. Biol. 2015, 1277, 1-14.
  58. Wang, S., Zhou, L., Wang, Z., Shi, X., Xu, G., Simultaneous metabolomics and lipidomics analysis based on novel heart-cutting two-dimensional liquid chromatography-mass spectrometry. Anal. Chim. Acta. 2017, 966, 34-40.
  59. Miyagi, Y., Higashiyama, M., Gochi, A., Akaike, M., Ishikawa, T., Miura, T., Saruki, N., Bando, E., Kimura, H., Imamura, F., Moriyama, M., Ikeda, I., Chiba, A., Oshita, F., Imaizumi, A., Yamamoto, H., Miyano, H., Horimoto, K., Tochikubo, O., Mitsushima, T., Yamakado, M., Okamoto, N., Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011, 6, e24143.
  60. Li, Y., Song, X., Zhao, X., Zou, L., Xu, G., Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014, 966, 147-153.
  61. Calderon-Santiago, M., Priego-Capote, F., Turck, N., Robin, X., Jurado-Gamez, B., Sanchez, J. C., Luque de Castro, M. D., Human sweat metabolomics for lung cancer screening. Anal. Bioanal. Chem. 2015, 407, 5381-5392.
  62. Gao, L., Wen, Z., Wu, C., Wen, T., Ong, C. N., Metabolic profiling of plasma from benign and malignant pulmonary nodules patients using mass spectrometry-based metabolomics. Metabolites 2013, 3, 539-551.
  63. Mathe, E. A., Patterson, A. D., Haznadar, M., Manna, S. K., Krausz, K. W., Bowman, E. D., Shields, P. G., Idle, J. R., Smith, P. B., Anami, K., Kazandjian, D. G., Hatzakis, E., Gonzalez, F. J., Harris, C. C., Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014, 74, 3259-3270.
  64. Xiang, C., Jin, S., Zhang, J., Chen, M., Xia, Y., Shu, Y., Guo, R., Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer. Int. J. Biol. Markers 2018, 33, 314-320.
  65. Wikoff, W. R., Hanash, S., DeFelice, B., Miyamoto, S., Barnett, M., Zhao, Y., Goodman, G., Feng, Z., Gandara, D., Fiehn, O., Taguchi, A., Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J. Clin. Oncol. 2015, 33, 3880-3886.
  66. Zhang, B., Zheng, A., Hydbring, P., Ambroise, G., Ouchida, A. T., Goiny, M., Vakifahmetoglu-Norberg, H., Norberg, E., PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis. Cell Rep. 2017, 19, 2289-2303.
  67. Zhang, W. C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., Soh, B. S., Sun, L. L., Tai, B. C., Nga, M. E., Bhakoo, K. K., Jayapal, S. R., Nichane, M., Yu, Q., Ahmed, D. A., Tan, C., Sing, W. P., Tam, J., Thirugananam, A., Noghabi, M. S., Pang, Y. H., Ang, H. S., Mitchell, W., Robson, P., Kaldis, P., Soo, R. A., Swarup, S., Lim, E. H., Lim, B., Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012, 148, 259-272.
  68. Currie, E., Schulze, A., Zechner, R., Walther, T. C., Farese, R. V., Jr., Cellular fatty acid metabolism and cancer. Cell Metab. 2013, 18, 153-161.
  69. Dong, J., Cai, X., Zhao, L., Xue, X., Zou, L., Zhang, X., Liang, X., Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 2010, 6, 478-488.
  70. Halket, J. M., Waterman, D., Przyborowska, A. M., Patel, R. K., Fraser, P. D., Bramley, P. M., Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J. Exp. Bot. 2005, 56, 219-243.
  71. Kaspar, H., Dettmer, K., Gronwald, W., Oefner, P. J., Automated GC-MS analysis of free amino acids in biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 870, 222-232.
  72. Tsugawa, H., Bamba, T., Shinohara, M, Nishiumi, S, Yoshida, M, Fukusaki, E., Practical non-targeted gas chromatography mass spectrometry-based metabolomics platform for metabolic phenotype analysis. J. Biosci. Bioeng. 2011, 112, 292-298.
  73. Pasikanti, K. K., Ho, P. C., Chan, E. C., Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites. Rapid. Commun. Mass Spectrom. 2008, 22, 2984-2992.
  74. Emwas, A. H., Al-Talla, Z. A., Kharbatia, N. M., Sample collection and preparation of biofluids and extracts for gas chromatography-mass spectrometry. Methods Mol. Biol. 2015, 1277, 75-90.
  75. Scalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B. S., van Ommen, B., Pujos-Guillot, E., Verheij, E., Wishart, D., Wopereis, S., Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics 2009, 5, 435-458.
  76. Hu, X., Li, H., Tang, P., Sun, J., Yuan, Q., Li, C., GC-MS-based metabolomics study of the responses to arachidonic acid in Blakeslea trispora. Fungal Genet. Biol. 2013, 57, 33-41.
  77. Birkemeyer, C., Kolasa, A., Kopka, J., Comprehensive chemical derivatization for gas chromatography-mass spectrometry-based multi-targeted profiling of the major phytohormones. J. Chromatogr. A 2003, 993, 89-102.
  78. Oliver, F., Joachim, K., Richard N, T., al, e., Identifi cation of uncommon plant metabolites based on calculation of elemental compositions using gas chromatography and quadrupole mass spectrometry. Anal. Chem. 2000, 72, 3573-3580.
  79. Poli, D., Carbognani, P., Corradi, M., Goldoni, M., Acampa, O., Balbi, B., Bianchi, L., Rusca, M., Mutti, A., Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Resp. Res. 2005, 6, 71-71.
  80. Wang, C., Dong, R., Wang, X., Lian, A., Chi, C., Ke, C., Guo, L., Liu, S., Zhao, W., Xu, G., Li, E., Exhaled volatile organic compounds as lung cancer biomarkers during one-lung ventilation. Sci. Rep. 2014, 4, 7312.
  81. Deng, C., Zhang, X., Li, N., Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 808, 269-277.
  82. Miyamoto, S., Taylor, S. L., Barupal, D. K., Taguchi, A., Wohlgemuth, G., Wikoff, W. R., Yoneda, K. Y., Gandara, D. R., Hanash, S. M., Kim, K., Fiehn, O., Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites 2015, 5, 192-210.
  83. Musharraf, S. G., Mazhar, S., Choudhary, M. I., Rizi, N., Atta ur, R., Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry. Sci. Rep. 2015, 5, 8607.
  84. Wikoff, W. R., Grapov, D., Fahrmann, J. F., DeFelice, B., Rom, W. N., Pass, H. I., Kim, K., Nguyen, U., Taylor, S. L., Gandara, D. R., Kelly, K., Fiehn, O., Miyamoto, S., Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev. Res. (Phila). 2015, 8, 410-418.
  85. Volpi N, M. F., Capillary electrophoresis of biomolecules. Springer, New York 2013
  86. Celebier, M., Ibanez, C., Simo, C., Cifuentes, A., A Foodomics approach: CE-MS for comparative metabolomics of colon cancer cells treated with dietary polyphenols. Methods Mol. Biol. 2012, 869, 185-195.
  87. Dudley, E., MALDI profiling and applications in medicine. Adv. Exp. Med. Biol. 2019, 1140, 27-43.
  88. Lee, G. K., Lee, H. S., Park, Y. S., Lee, J. H., Lee, S. C., Lee, J. H., Lee, S. J., Shanta, S. R., Park, H. M., Kim, H. R., Kim, I. H., Kim, Y. H., Zo, J. I., Kim, K. P., Kim, H. K., Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. Lung Cancer 2012, 76, 197-203.
  89. Gámez-Pozo, A., Sánchez-Navarro, I., Nistal, M., Calvo, E., Madero, R., Díaz, E., Camafeita, E., de Castro, J., López, J. A., González-Barón, M., Espinosa, E., Fresno Vara, J. Á., MALDI profiling of human lung cancer subtypes. PLoS One 2009, 4, e7731.
  90. Yildiz, P. B., Shyr, Y., Rahman, J. S., Wardwell, N. R., Zimmerman, L. J., Shakhtour, B., Gray, W. H., Chen, S., Li, M., Roder, H., Liebler, D. C., Bigbee, W. L., Siegfried, J. M., Weissfeld, J. L., Gonzalez, A. L., Ninan, M., Johnson, D. H., Carbone, D. P., Caprioli, R. M., Massion, P. P., Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J. Thorac. Oncol. 2007, 2, 893-901.
  91. Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O'Brien, J. P., Pierce, K. A., Gui, D. Y., Sullivan, L. B., Wasylenko, T. M., Subbaraj, L., Chin, C. R., Stephanopolous, G., Mott, B. T., Jacks, T., Clish, C. B., Vander Heiden, M. G., Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 2016, 23, 517-528.
  92. Yang, Y., Metabolic reprogramming of human lung cancer cells and ex vivo tissues revealed by UHR-FTMS analysis of small amino and carboxyl metabolites. theses and dissertations. Toxicol. Cancer Biol. 2017, https://doi.org/10.13023/ETD.2017.020.
  93. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., Cantley, L. C., The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452, 230-233.
  94. Ye, J., Mancuso, A., Tong, X., Ward, P. S., Fan, J., Rabinowitz, J. D., Thompson, C. B., Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad Sci. 2012, 109, 6904-6909.
  95. Faubert, B., Li, K. Y., Cai, L., Hensley, C. T., Kim, J., Zacharias, L. G., Yang, C., Do, Q. N., Doucette, S., Burguete, D., Li, H., Huet, G., Yuan, Q., Wigal, T., Butt, Y., Ni, M., Torrealba, J., Oliver, D., Lenkinski, R. E., Malloy, C. R., Wachsmann, J. W., Young, J. D., Kernstine, K., DeBerardinis, R. J., Lactate metabolism in human lung tumors. Cell 2017, 171, 358-371.e359.
  96. Fahrmann, J. F., Grapov, D. D., Wanichthanarak, K., DeFelice, B. C., Salemi, M. R., Rom, W. N., Gandara, D. R., Phinney, B. S., Fiehn, O., Pass, H., Miyamoto, S., Integrated metabolomics and proteomics highlight altered nicotinamide- and polyamine pathways in lung adenocarcinoma. Carcinogenesis 2017
  97. Puchades-Carrasco, L., Jantus-Lewintre, E., Perez-Rambla, C., Garcia-Garcia, F., Lucas, R., Calabuig, S., Blasco, A., Dopazo, J., Camps, C., Pineda-Lucena, A., Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget 2016, 7, 12904-12916.
  98. Pendaries, C., Tronchere, H., Plantavid, M., Payrastre, B., Phosphoinositide signaling disorders in human diseases. FEBS Lett. 2003, 546, 25-31.
  99. Guo, Y., Wang, X., Qiu, L., Qin, X., Liu, H., Wang, Y., Li, F., Wang, X., Chen, G., Song, G., Li, F., Guo, S., Li, Z., Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clin. Chim. Acta. 2012, 414, 135-141.
  100. Yu, Z., Chen, H., Ai, J., Zhu, Y., Li, Y., Borgia, J. A., Yang, J. S., Zhang, J., Jiang, B., Gu, W., Deng, Y., Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer. Oncotarget 2017, 8, 107899-107906.
  101. Murphy, R. A., Bureyko, T. F., Mourtzakis, M., Chu, Q. S., Clandinin, M. T., Reiman, T., Mazurak, V. C., Aberrations in plasma phospholipid fatty acids in lung cancer patients. Lipids 2012, 47, 363-369.
  102. Fahrmann, J. F., Grapov, D., DeFelice, B. C., Taylor, S., Kim, K., Kelly, K., Wikoff, W. R., Pass, H., Rom, W. N., Fiehn, O., Miyamoto, S., Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomark. 2016, 16, 609-617.
  103. Marien, E., Meister, M., Muley, T., Fieuws, S., Bordel, S., Derua, R., Spraggins, J., Van de Plas, R., Dehairs, J., Wouters, J., Bagadi, M., Dienemann, H., Thomas, M., Schnabel, P. A., Caprioli, R. M., Waelkens, E., Swinnen, J. V., Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. Int. J. Cancer 2015, 137, 1539-1548.
  104. Zinrajh, D., Horl, G., Jurgens, G., Marc, J., Sok, M., Cerne, D., Increased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival. Oncol. Lett. 2014, 7, 2175-2179.
  105. Huang, L. J., Chen, S. X., Luo, W. J., Jiang, H. H., Zhang, P. F., Yi, H., Proteomic analysis of secreted proteins of non-small cell lung cancer. Ai. Zheng 2006, 25, 1361-1367.
  106. Yu, G. P., Chen, G. Q., Wu, S., Shen, K., Ji, Y., The expression of PEBP4 protein in lung squamous cell carcinoma. Tumour Biol. 2011, 32, 1257-1263.
  107. Wang, X., Li, N., Liu, B., Sun, H., Chen, T., Li, H., Qiu, J., Zhang, L., Wan, T., Cao, X., A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J. Biol. Chem. 2004, 279, 45855-45864.
  108. Kupert, E., Anderson, M., Liu, Y., Succop, P., Levin, L., Wang, J., Wikenheiser-brokamp, K., Chen, P., Pinney, S. M., Macdonald, T., Dong, Z., Starnes, S., Lu, S., Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer 2011, 11, 513.
  109. Zhang, M., Xu, Z. G., Shi, Z., Shao, D., Li, O., Li, W., Li, Z. J., Wang, K. Z., Chen, L., Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A(2) and peroxisome proliferator-activated receptor gamma. Mol. Cell. Biochem. 2011, 355, 233-240.
  110. Liu, J., Mazzone, P. J., Cata, J. P., Kurz, A., Bauer, M., Mascha, E. J., Sessler, D. I., Serum free fatty acid biomarkers of lung cancer. Chest 2014, 146, 670-679.
  111. Granata, F., Frattini, A., Loffredo, S., Staiano, R. I., Petraroli, A., Ribatti, D., Oslund, R., Gelb, M. H., Lambeau, G., Marone, G., Triggiani, M., Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J. Immunol. 2010, 184, 5232-5241.
  112. Weiser-Evans, M. C., Wang, X. Q., Amin, J., Van Putten, V., Choudhary, R., Winn, R. A., Scheinman, R., Simpson, P., Geraci, M. W., Nemenoff, R. A., Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009, 69, 1733-1738.
  113. Linkous, A. G., Yazlovitskaya, E. M., Hallahan, D. E., Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J. Natl. Cancer Inst. 2010, 102, 1398-1412.
  114. Kim, H. A., Kim, K. J., Seo, K. H., Lee, H. K., Im, S. Y., PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis. FEBS Lett. 2012, 586, 4296-4302.
  115. Kerjaschki, D., Bago-Horvath, Z., Rudas, M., Sexl, V., Schneckenleithner, C., Wolbank, S., Bartel, G., Krieger, S., Kalt, R., Hantusch, B., Keller, T., Nagy-Bojarszky, K., Huttary, N., Raab, I., Lackner, K., Krautgasser, K., Schachner, H., Kaserer, K., Rezar, S., Madlener, S., Vonach, C., Davidovits, A., Nosaka, H., Hammerle, M., Viola, K., Dolznig, H., Schreiber, M., Nader, A., Mikulits, W., Gnant, M., Hirakawa, S., Detmar, M., Alitalo, K., Nijman, S., Offner, F., Maier, T. J., Steinhilber, D., Krupitza, G., Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Invest. 2011, 121, 2000-2012.
  116. Paige, M., Saprito, M. S., Bunyan, D. A., Shim, Y. M., HPLC quantification of 5-hydroxyeicosatetraenoic acid in human lung cancer tissues. Biomed. Chromatogr. 2009, 23, 817-821.
  117. Sanchez-Rodriguez, P., Rodriguez, M. C., Sanchez-Yague, J., Identification of potential erythrocyte phospholipid fatty acid biomarkers of advanced lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer. Tumour Biol. 2015, 36, 5687-5698.
  118. Hernandez-Hernandez, A., Rodriguez, M. C., Lopez-Revuelta, A., Sanchez-Gallego, J. I., Shnyrov, V., Llanillo, M., Sanchez-Yague, J., Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cells Mol. Dis. 2006, 36, 355-363.
  119. de Castro, J., Hernandez-Hernandez, A., Rodriguez, M. C., Llanillo, M., Sanchez-Yague, J., Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest. 2006, 24, 339-345.
  120. De Castro, J., Hernandez-Hernandez, A., Rodriguez, M. C., Sardina, J. L., Llanillo, M., Sanchez-Yague, J., Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 2007, 18, 43-51.
  121. Koma, Y., Onishi, A., Matsuoka, H., Oda, N., Yokota, N., Matsumoto, Y., Koyama, M., Okada, N., Nakashima, N., Masuya, D., Yoshimatsu, H., Suzuki, Y., Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One 2013, 8, e80240.
Article Info
Journal
Journal of separation science
Abbr.
J Sep Sci
ISSN
1615-9314
DOI
10.1002/jssc.201900736
Published
2020-01-00
Epub
2019-00-10
Pages
120-133
Language
English
Region
Germany
NLM ID
101088554
Subset
IM
Grants
National Key Research and Development Program of China · 2017YFC0906900
National Key Research and Development Program of China · 21705147
National Key Research and Development Program of China · 21876169
National Natural Science Foundation of China
External Links
PubMed source DOI: 10.1002/jssc.201900736 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2